Author:
Haslam Alyson,Prasad Vinay
Abstract
Abstract
Background
The economic and health burden of COVID-19 has transformed the healthcare system in the US. Hospitals have adapted to the heterogeneity in long COVID symptoms, and the sheer number of people affected by this condition, by building long COVID centers and programs.
Objective
We sought to describe characteristics, services, and clinical trials of long COVID centers at top US hospitals.
Design
Cross-sectional analysis.
Participants
Long COVID treatment programs or centers at top US hospitals.
Exposures
Frequency of long COVID centers, eligibility for being treated, the services they provide, specialist to whom the patients may be referred, and the long COVID clinical trials in which these hospitals participate.
Findings
Most top hospitals in the US (n = 43/50; 86%) offer long COVID services. 65% (28/43) did not describe the services provided. 12 (28%) required a referral from a primary care physician. The most common services were meeting with a team member (n = 20; 47%), ordering lab and/or radiology services (n = 8; 18.6%), and administering a physical exam (n = 7; 16%). 7 (16%) centers/programs treated only adults; 5 (12%) treated both adults and children, and 31 (72%) did not specify. The most common specialists described were psychology (n = 25; 58%), neurology (n = 25; 58%), and pulmonary (n = 24; 56%). Sixty-three trials (of 134 long COVID clinical trials) had at least one top hospital listed as a study site. The median number of clinical trials that each hospital sponsored or was a study site was 2 (interquartile range: 1, 3).
Conclusions and relevance
We find that services offered at long COVID clinics at top hospitals in the US often include meeting with a team member and referrals to a wide range of specialists. The diversity in long COVID services offered parallels the diversity in long COVID symptoms, suggesting a need for better consensus in developing and delivering treatment.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Haslam A, Olivier T, Prasad V. The definition of long COVID used in interventional studies. Eur J Clin Invest March. 2023;25:e13989. https://doi.org/10.1111/eci.13989.
2. Haslam A, Prasad V. Comparability of control and comparison groups in studies assessing long COVID. Am J Med. January 2023;25. https://doi.org/10.1016/j.amjmed.2023.01.005.
3. National Center for Health Statistics. Nearly One in Five American Adults Who Have Had COVID-19 Still Have. Long COVID. Centers for Disease Control and Prevention. June 22, 2022. Accessed January 10, 2023. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm.
4. Cutler DM. The economic cost of long COVID: an update. July; 2022.
5. McKinsey Executive Briefing. Coronavirus’ business impact: Evolving perspective - COVID-19: Briefing note #98. McKinsey. March 30. 2022. Accessed July 7, 2023. https://www.mckinsey.com/capabilities/risk-and-resilience/our-insights/covid-19-implications-for-business.